NASDAQ · Biotechnology · USD
PMGC Holdings Inc. (ELAB) Stock Analysis
PMGC Holdings Inc. (ELAB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ELAB Key Statistics
As of Oct 21, 2026Trading
- Open
- $2.80
- Previous Close
- $2.81
- Day's Range
- 2.76–2.81
- 52-Week Range
- 2.59–1,591.68
- Volume
- 2.77K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- −0.27
Valuation
- Market Cap
- $2.25M
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 0.87
Financials (FY)
- Revenue (FY)
- $590.08K
- Net Income (FY)
- −$7.75M
- Shares Outstanding
- 809.58K
- 1-Year Return
- −99.83%
Dividend and dates
- Avg Volume
- 49.99K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ELAB closed at $2.78, −99.83% over 1 year.
PMGC Holdings Inc. (ELAB) has a market capitalization of $2.25M.
In fiscal 2025, ELAB reported revenue of $590.08K.
ELAB Stock Return by Calendar Year
PMGC Holdings Inc. (ELAB) return since Nov 2023: what $10,000 became
- 1 year
- $10,000 $17
- −99.83%
- Since Nov 2023
- $10,000 $0.01
- −99.9999%
If you had invested $10,000 in PMGC Holdings Inc. (ELAB) at the close on November 21, 2023, the earliest close on record here, it would have been worth $0.01 at the close on October 21, 2026: −99.9999% in total, −99.23% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −99.22% |
| 2025 | −97.37% |
| 2024 | −99.37% |
| 2023 (partial year) | −46.24% |
As of October 21, 2026.
ELAB Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $590.08K | −$7.75M | −1,313.0% |
| 2024 | $0.00 | −$6.25M | — |
| 2023 | $0.00 | −$4.30M | — |
| 2022 | $766.28K | −$1.80M | −234.9% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $590.08K | $185.31K | −$6.82M | −$7.75M | −1,313.0% |
| 2024 | $0.00 | $0.00 | −$3.66M | −$6.25M | — |
| 2023 | $0.00 | $1.13M | −$1.13M | −$4.30M | — |
| 2022 | $766.28K | $447.31K | −$1.79M | −$1.80M | −234.9% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
ELAB Valuation vs Biotechnology Median
Median of 608 stocks| Metric | ELAB | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 0.87 | 13.30 | 0.1x the median |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
PMGC Holdings Inc. Announces DBA as NorthStrive Holdings, Inc., Trademark License Agreement, and Website Update
YahooPMGC Holdings Registers A Doing-Business-As Name As Northstrive Holdings, And Enters Into A Trademark License Agreement With NorthStrive Companies
BenzingaPMGC Holdings (Nasdaq: ELAB) Announces Completion of $100 Million SPAC IPO, Launching NorthStrive Acquisition Corp. I (Nasdaq: NSAI) as First in Planned SPAC Sponsorship Franchise to Expand M&A Strategy
YahooPMGC Holdings’ Northstrive Biosciences Executes Statement Of Work With Charles River To Conduct Analytical Characterization Supporting Development Of EL-22 And EL-32 Engineered Probiotic Programs
BenzingaPMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings
YahooPMGC Holdings’ Northstrive Amends Development And License Agreement With Yuva Biosciences To Launch Three-Phase Program Advancing Four AI-Discovered Compounds And Updating AI Scope, IP, Field Of Use, And Financial Terms
Benzinga
All 10 articles ↓Show fewer ↑
PMGC Announces 1-For-10 Reverse Stock Split, Effective Aug. 21
BenzingaPMGC Holdings Confirms It Is In Compliance With Nasdaq’s Newly Approved Market Value Of Listed Securities Continued-Listing Requirement
BenzingaPMGC Holdings’ A&B Aerospace Enters Into Long-Term Agreement With PAD Group To Manufacture And Supply Precision-Machined Aerospace And Defense Components
BenzingaPMGC Holdings Unit NorthStrive Defense Tech Enters Project Services Agreement With Deploy360 For Validation And Testing Of Patented GPS-Denied Autonomous Navigation Technology
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B